Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen Stock Plummets 14 Percent on Unreliable Q2 Results

NEW YORK, Nov. 17 (GenomeWeb News) - Shares in Ciphergen tumbled 13.87 percent, or $.24, to $1.49 in mid-afternoon trading after Ciphergen yesterday said that its second-quarter earnings report should "no longer be relied upon."

 

As GenomeWeb News reported earlier this morning, an audit committee appointed by Ciphergen said second-quarter earnings should be restated to correct the $500,000 in revenue that had apparently been improperly recorded from that period.

 

Ciphergen stock has had a rough week. Earlier this week, Nasdaq removed Ciphergen from its Nasdaq Biotechnology Index. The exchange also said that the company's common stock will be delisted from the Nasdaq National Market as of Nov. 25 for failing to file its third-quarter earnings report.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.